<DOC>
	<DOCNO>NCT01275196</DOCNO>
	<brief_summary>The study compare efficacy safety Nilotinib versus Imatinib newly diagnose Chinese patient CML-CP .</brief_summary>
	<brief_title>Safety Efficacy Nilotinib vs. Imatinib Treatment Newly Diagnosed Chinese Ph+ CML-CP Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients Chinese ethnicity great equal 18 year age ECOG 0 , 1 , 2 . Patients CMLCP ( Ph+ ) within 6 month diagnosis ( date initial diagnosis date first cytogenetic analysis ) . Standard conventional cytogenetic analysis must do bone marrow . ( FISH use ) Diagnosis chronic myelogenous leukemia chronic phase cytogenetic confirmation presence Philadelphia chromosome ( 9 ; 22 translocation ; le 20 metaphase may use diagnosis Documented chronic phase CML meet criterion define : &lt; 15 % blast peripheral blood bone marrow &lt; 30 % blast plus promyelocytes peripheral blood bone marrow &lt; 20 % basophils peripheral blood ≥ 100 x 109/L ( ≥ 100,000/mm3 ) platelets No evidence extramedullary leukemic involvement , exception hepatosplenomegaly Adequate organ function define : Total bilirubin &lt; 1.5 x ULN SGOT SGPT &lt; 2.5 x ULN Creatinine &lt; 1.5 x ULN Serum amylase lipase ≤ 1.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate . Patients must follow laboratory value ( ≥ LLN ( low limit normal ) correct within normal limit supplement prior first dose study medication . ) : Potassium ≥ LLN Magnesium ≥ LLN Phosphate ≥ LLN Total calcium ( correct serum albumin ) ≥ LLN . Ability provide write informed consent prior study related screening procedure perform . Patients previously document T315I mutation ; Treatment tyrosine kinase inhibitor ( ) prior study entry allow , except follow situation : emergent case patient require disease management await study start , commercial supply Gleevec/Glivec dose may prescribe patient longer 2 week duration . Treatment IFN 3 month . Impaired cardiac function include one following : Complete leave bundle branch block Long QT syndrome know family history long QT syndrome . History presence clinically significant ventricular atrial tachyarrhythmias Clinically significant rest bradycardia ( &lt; 50 beat per minute ) QTc &gt; 450 msec If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc History clinically document myocardial infarction within past 12 month History unstable angina ( last 12 month ) Other clinically significant heart disease ( e.g. , congestive heart failure uncontrolled hypertension ) . Known cytopathologically confirm CNS infiltration ( absence suspicion CNS involvement , lumbar puncture require ) . Severe uncontrolled medical condition ( i.e . uncontrolled diabetes , active uncontrolled infection ) . History significant congenital acquire bleed disorder unrelated cancer . Major surgery within 4 week prior Day 1 study recover prior surgery . Treatment investigational agent ( define use accordance approve indication ) within 30 day Day 1 . History noncompliance medical regimen inability grant consent . Patients another primary malignancy except primary malignancy neither currently clinically significant require active intervention Patients actively receive therapy strong CYP3A4 inhibitor ( e.g. , erythromycin , ketoconazole , itraconazole , voriconazole , clarithromycin , telithromycin , ritonavir , mibefradil ) treatment either discontinue switched different medication prior start study drug . See link complete list medication : http : //medicine.iupui.edu/flockhart/table.htm reference Protocol post text appendix 1 . Patients actively receive therapy strong CYP3A4 inducer ( e.g. , dexamthasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbitol , St. John 's Wort ) treatment either discontinue switched different medication prior start study drug . See link complete list medication : http : //medicine.iupui.edu/flockhart/table.htm reference Protocol post text appendix 1 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection , gastric bypass surgery ) History acute pancreatitis within 1 year study entry past medical history chronic pancreatitis . Acute chronic liver , pancreatic severe renal disease consider unrelated disease . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug ( Please see http : //www.torsades.org/medicalpros/druglists/printabledruglist.cfm comprehensive list agent prolong QT interval ) . Patients : ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test prior baseline ( ) female childbearing potential unwilling use contraceptive precaution throughout trial ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Newly diagnose ,</keyword>
	<keyword>Ph+ chronic myeloid leukemia ,</keyword>
	<keyword>CML-CP</keyword>
</DOC>